Fig. 2

Mean SF-36 domain scores for adalimumab and sarilumab (combined baseline^† and week 24) by IL-6 tertile^§. The nominal p value for the IL-6 tertile-by-treatment interaction using the low tertile as reference was ≥ 0.05 for all SF-36 domains except PF. ^†Baseline combined scores are presented; change from baseline for each group cannot be inferred from the figure alone. Each 10-point interval represents twice the MCID for the SF-36 domain scores. ^‡p value of the between-group difference in LSM change from baseline < 0.05 within each IL-6 tertile. ^§Low (1.6–7.1 pg/mL), medium (7.2–39.5 pg/mL), high (39.6–692.3 pg/mL). BP bodily pain, FACIT Functional Assessment of Chronic Illness Therapy, GH general health, IL-6 interleukin-6, LSM least squares mean, MCID minimal clinically important differences, MH mental health, PF physical functioning, RE role-emotional, RP role-physical, SF social functioning, SF-36 Short Form 36, VAS visual analog scale, VT vitality